Reference
1. 1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9.
2. Hussain M, Khurram Syed S, Fatima M, Shaukat S, Saadullah M, Alqahtani AM, et al. Acute respiratory distress syndrom and COVID-19: A literature review. J Inflamm Res. 2021;14:7225-42.
3. Gong B, Huang L, He Y, Xie W, Yin Y, Shi Y, et al. A genetic variant in IL-6 lowering its expression is protective for critical patients with COVID-19. Signal Transduct Target Ther. 2022;7(1):112.
4. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez
L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62-75.
5. Vatansever HS, Becer E. Relationship between IL-6 and COVID-19: To be considered during treatment. Future Virol. 2020;15(12):817-22.
6. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954.
7. Silva MJ, Ribeiro LR, Lima KV, Lima LN. Adaptive immunity to SARS-CoV-2 infection: A systematic review. Front Immunol. 2022;13:1001198.
8. Haukim N, Bidwell JL, Smith AJ, Keen LJ, Gallagher G, Kimberly R, et al. Cytokine gene polymorphism in human disease: On-line databases, Supplement 2. Genes Immun, 2002;3(6):313–30.
9. Rehman K, Akash MS, Liaqat A, Kamal S, Qadir MI, Rasul A. Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. Crit Rev Eukaryot Gene Expr. 2017;27(3):229-36.
10. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295.
11. Rashid P, Salih GF. Genetic polymorphism between the Sorani and Hawrami kurdish populations and COVID-19 outcome. Mol Biol Rep. 2023;50(6):5177-83.
12. Villar-Fincheira P, Sanhueza-Olivares F, Norambuena-Soto I, Cancino-Arenas N, Hernandez-Vargas F, Troncoso R, et al. Role of interleukin-6 in vascular health and disease. Front Mol Biosci. 2021;8:641734.
13. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti- inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta Mol Cell Res. 2011;1813(5):878-88.
14. Mauer J, Denson JL, Brüning JC. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 2015;36(2):92-101.
15. Barrett D. IL-6 blockade in cytokine storm syndromes. In: Cron RQ, Behrens EM (eds). Cytokine storm syndrome. Springer; 2019, pp. 561-8.
16. Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 pathway from discovery to clinical implementation. Front Immunol. 2016;7:550.
17. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39:529-39.
18. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C- reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.
19. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020;9(1):1123-30.
20. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74.
21. Falahi S, Zamanian MH, Feizollahi P, Rezaiemanesh A, Salari F, Mahmoudi Z, et al. Evaluation of the relationship between IL-6 gene single nucleotide polymorphisms and the severity of COVID-19 in an Iranian population. Cytokine. 2022;154:155889.
22. Rashid PM, Salih GF. Genetic polymorphism of interlukine-6 in asymptomatic and ICU-admitted COVID-19 patients. 2023:1-14.
23. Yektay S, Alamdary A, Khanizadeh S, Mohammadi R, Talei G, Ajorloo M. Association between the interleukin–6 (IL-6) polymorphism in− 174 G/C genotype (rs1800795) with the Covid-19 pathogenicity. Hum Gene. 2023;37:201204.
24. Altamemi IA, Khlebos AH. IL-6 predict disease severity and potential therapeutic target in COVID-19 patient. Ann Rom Soc Cell Biol. 2021;25(2):2173-80.
25. Ghazy AA. Influence of IL-6 rs1800795 and IL-8 rs2227306 polymorphisms on COVID-19 outcome. J Infect Dev Ctries. 2023;17(03):327-34.
26. Khafaei M, Asghari R, Zafari F, Sadeghi M. Impact of IL-6 rs1800795 and IL-17A rs2275913 gene polymorphisms on the COVID-19 prognosis and susceptibility in a sample of Iranian patients. Cytokine. 2024;174:156445.
27. Rodrigues FB, da Silva R, Santos EF, de Brito MT, da Silva AL, de Meira Leite M, et al. Association of polymorphisms of IL-6 pathway genes (IL-6, IL-6R, and IL6ST) with COVID-19 severity in an Amazonian population. Viruses. 2023;15(5):1197.